Goodkin DE - Search Results

1

Psychological stress and the subsequent appearance of new brain MRI lesions in MS.

Mohr DC, Goodkin DE, Bacchetti P, Boudewyn AC, Huang L, Marrietta P, Cheuk W, Dee B. Mohr DC, et al. Among authors: goodkin de. Neurology. 2000 Jul 12;55(1):55-61. doi: 10.1212/wnl.55.1.55. Neurology. 2000. PMID: 10891906

2

Moderating effects of coping on the relationship between stress and the development of new brain lesions in multiple sclerosis.

Mohr DC, Goodkin DE, Nelson S, Cox D, Weiner M. Mohr DC, et al. Among authors: goodkin de. Psychosom Med. 2002 Sep-Oct;64(5):803-9. doi: 10.1097/01.psy.0000024238.11538.ec. Psychosom Med. 2002. PMID: 12271111 Free PMC article.

3

IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D. Waubant E, et al. Neurology. 2003 Jan 14;60(1):52-7. doi: 10.1212/wnl.60.1.52. Neurology. 2003. PMID: 12525717 Clinical Trial.

4

A serial study of new MS lesions and the white matter from which they arise.

Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. Goodkin DE, et al. Neurology. 1998 Dec;51(6):1689-97. doi: 10.1212/wnl.51.6.1689. Neurology. 1998. PMID: 9855524

5

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.

Mohr DC, Likosky W, Dwyer P, Van Der Wende J, Boudewyn AC, Goodkin DE. Mohr DC, et al. Among authors: goodkin de. Arch Neurol. 1999 Oct;56(10):1263-5. doi: 10.1001/archneur.56.10.1263. Arch Neurol. 1999. PMID: 10520943

6

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. Waubant E, et al. Among authors: goodkin de. Neurology. 1999 Oct 22;53(7):1397-401. doi: 10.1212/wnl.53.7.1397. Neurology. 1999. PMID: 10534241

7

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Kita M, et al. Among authors: goodkin de. Neurology. 2000 May 9;54(9):1741-5. doi: 10.1212/wnl.54.9.1741. Neurology. 2000. PMID: 10802778

8

Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis.

Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Mohr DC, et al. Among authors: goodkin de. Arch Neurol. 2001 Jul;58(7):1081-6. doi: 10.1001/archneur.58.7.1081. Arch Neurol. 2001. PMID: 11448297 Clinical Trial.

9

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS.

Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, Goodkin D. Waubant E, et al. J Neuroimmunol. 2001 Jan 1;112(1-2):139-45. doi: 10.1016/s0165-5728(00)00355-6. J Neuroimmunol. 2001. PMID: 11108942

10

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.

Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Mohr DC, et al. Among authors: goodkin de. Arch Neurol. 1997 May;54(5):531-3. doi: 10.1001/archneur.1997.00550170015009. Arch Neurol. 1997. PMID: 9152109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters